Replies to post #352970 on Innovation Pharmaceuticals Inc (IPIX)

[Minnesinger]

It would be nice to hear more about...

Brilacidin's potential against other types of coronaviruses, but I'm more interested in this quote from the 11/16/20 10Q:

Our oral program development will be supported by a modified release oral capsule formulation now in development. Regulatory approval will be sought to initiate a proposed placebo-controlled Phase 2 clinical trial in UC patients, targeted to begin in the first half of calendar year 2021 once drug supply is available.

We're about halfway through the first half of 2021 and we haven't heard a word on B-UC since it was mentioned in the 10Q. Will LE be able to fulfill the guidance he's given and hit the target? I hope so. Perhaps I'll be pleasantly surprised this week...

[farrell90]

IPIX first announced the pancoronavirus research in 06/2020:
"Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL) are collaborating on a federal grant application to be submitted this week"

"The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the current in vitro testing of Brilacidin to in vivo testing. Longer-term objectives include potentially performing additional research to develop Brilacidin as a broad-spectrum antiviral, with possible application beyond coronaviruses, e.g., treating other viruses, such as encephalitic alphaviruses and filoviruses."

"The ongoing Brilacidin anti-SARS-CoV-2 research being conducted at the RBL is separate from the ongoing research being performed at a Public Health Research Institute (PHRI). The lead researchers at both the RBL and at the PHRI have informed the Company they plan to submit their findings, separately, upon completion of in vitro testing, for peer-review publication."

WAKEFIELD, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin mimetic, has the potential to treat other endemic human coronaviruses (H-CoVs), such as those causing common colds, and not just SARS-CoV-2, the novel coronavirus responsible for the ongoing global COVID-19 pandemic.
Research shows Brilacidin exerted potent in vitro inhibition of multiple strains of H-CoVs. On completion of testing, the H-CoV findings are expected to be submitted for peer-review publication. The Company is evaluating these data alongside previously obtained SARS-CoV-2 data, strategizing with its scientific advisors and consultants, to develop Brilacidin as a “pan-coronavirus” therapeutic...

The Company is planning to conduct additional in vitro and in vivo Brilacidin studies on multiple coronaviruses, to further inform the drug’s anti-coronavirus properties and prepare for potential future clinical testing.

My guess is this in vitro studies should be done soon. The in vivo animal studies may take longer. I would expect the labs would also be studying the coronavirus mutations. I am looking forward to seeing another Brilacidin publication.

GLTA'

Farrell


https://www.globenewswire.com/news-release/2020/11/30/2136611/0/en/Innovation-Pharmaceuticals-COVID-19-Clinical-Trial-to-Support-Additional-Development-of-Brilacidin-as-a-Pan-Coronavirus-Therapeutic.html

https://www.globenewswire.com/news-release/2020/06/11/2046799/0/en/Innovation-Pharmaceuticals-Collaborating-with-Regional-Biocontainment-Lab-on-Grant-Application-to-Research-Brilacidin-as-a-Pan-Coronavirus-Therapeutic.html